These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
804 related articles for article (PubMed ID: 27613365)
1. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo. Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365 [TBL] [Abstract][Full Text] [Related]
2. Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice. Zhao W; Guo Z; Zheng M; Zhang J; Wang B; Li P; Fu L; Liu S Int J Antimicrob Agents; 2014 Feb; 43(2):148-53. PubMed ID: 24290060 [TBL] [Abstract][Full Text] [Related]
3. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. Zou L; Liu M; Wang Y; Lu J; Pang Y Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151 [TBL] [Abstract][Full Text] [Related]
4. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis. Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. Mushtaq F; Raza SM; Ahmad A; Aslam H; Adeel A; Saleem S; Ahmad I PLoS One; 2023; 18(10):e0293194. PubMed ID: 37883448 [TBL] [Abstract][Full Text] [Related]
6. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925 [TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia. Vīksna A; Sadovska D; Berge I; Bogdanova I; Vaivode A; Freimane L; Norvaiša I; Ozere I; Ranka R BMC Infect Dis; 2023 Sep; 23(1):638. PubMed ID: 37770850 [TBL] [Abstract][Full Text] [Related]
8. A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen. Zainabadi K; Vilbrun SC; Mathurin LD; Walsh KF; Pape JW; Fitzgerald DW; Lee MH J Infect Dis; 2024 Aug; 230(2):e447-e456. PubMed ID: 38060827 [TBL] [Abstract][Full Text] [Related]
9. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A]. Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422 [No Abstract] [Full Text] [Related]
10. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates]. Coban AY; Bilgin K; Uzun M; Durupinar B Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615 [TBL] [Abstract][Full Text] [Related]
11. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China. Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023 [TBL] [Abstract][Full Text] [Related]
12. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. Zhang Z; Li T; Qu G; Pang Y; Zhao Y Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737 [TBL] [Abstract][Full Text] [Related]
13. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878 [TBL] [Abstract][Full Text] [Related]
14. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models. Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558 [TBL] [Abstract][Full Text] [Related]
17. In Vitro Evaluation of Linezolid and Meropenem Against Clinical Isolates of Multi Drug Resistant Tuberculosis By Mycobacterial Growth Indicator Tube (MGIT) 960. Mirza IA; Satti L; Khan FA; Khan KA J Coll Physicians Surg Pak; 2015 Jun; 25(6):427-30. PubMed ID: 26100995 [TBL] [Abstract][Full Text] [Related]
18. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Rey-Jurado E; Tudó G; de la Bellacasa JP; Espasa M; González-Martín J Int J Antimicrob Agents; 2013 Mar; 41(3):278-80. PubMed ID: 23312604 [TBL] [Abstract][Full Text] [Related]
19. Identifying Regimens Containing TBI-166, a New Drug Candidate against Zhang Y; Zhu H; Fu L; Wang B; Guo S; Chen X; Liu Z; Huang H; Yang T; Lu Y Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061157 [TBL] [Abstract][Full Text] [Related]
20. [Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates]. Bektöre B; Haznedaroğlu T; Baylan O; Ozyurt M; Ozkütük N; Satana D; Cavuşoğlu C; Seber E Mikrobiyol Bul; 2013 Jan; 47(1):59-70. PubMed ID: 23390903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]